What BPC-157 actually is
BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids. It is derived from a protein called BPC that is found naturally in human gastric juice. The peptide was first characterized by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s, and the same group has produced the majority of published research on it[1].
The "body protection" label comes from the remarkable range of tissue-protective effects demonstrated in animal models. BPC-157 has been shown to accelerate healing of tendons, ligaments, muscle, bone, and skin in rodent studies[2]. It has also shown protective effects on the gastrointestinal tract, liver, and brain in various injury and toxicity models[3].
The critical caveat: virtually all published data on BPC-157 comes from animal studies. As of 2026, there are no published Phase I, Phase II, or Phase III human clinical trials. This means dosing, pharmacokinetics, safety profile, and efficacy in humans are extrapolated from animal data, not established by direct human evidence. That doesn't mean BPC-157 doesn't work or isn't safe — it means the evidence base is pre-clinical, and personal monitoring becomes especially important.
What BPC-157 does in the body
Understanding the proposed mechanisms of BPC-157 helps explain which blood markers to track. The published animal literature describes several key pathways:
Angiogenesis and VEGF upregulation
BPC-157 promotes the formation of new blood vessels (angiogenesis) by upregulating vascular endothelial growth factor (VEGF) and its receptor systems[4]. In rat models, BPC-157 administration led to significantly increased VEGF expression at wound sites, accelerating the formation of granulation tissue. This is believed to be one of the primary mechanisms behind its wound-healing and tendon-repair effects.
Nitric oxide system modulation
BPC-157 interacts with the nitric oxide (NO) system, which is involved in vasodilation, blood pressure regulation, and inflammatory signaling. Studies have shown that BPC-157 can counteract both NO-excess and NO-deficiency states in animal models, suggesting a modulatory rather than unidirectional effect[5]. This has implications for blood pressure and vascular function.
Gastrointestinal cytoprotection
As a gastric juice-derived peptide, BPC-157 has extensive research supporting its protective effects on the GI tract. It has demonstrated efficacy in animal models of gastric ulcers, inflammatory bowel disease, esophageal damage, and intestinal anastomosis healing[6]. These effects appear to be mediated through multiple pathways including anti-inflammatory signaling, angiogenesis, and modulation of the dopaminergic system.
Hepatoprotective effects
Multiple animal studies have shown BPC-157 to be protective against liver injury. Sikiric et al. demonstrated that BPC-157 counteracted liver damage induced by chronic alcohol administration, NSAIDs, and hepatotoxic agents in rat models[7]. In these studies, animals treated with BPC-157 showed lower ALT and AST elevations compared to untreated controls.
Anti-inflammatory signaling
BPC-157 appears to modulate inflammatory cascades. Animal studies have documented reductions in pro-inflammatory cytokines (TNF-alpha, IL-6) in models of systemic inflammation[8]. This anti-inflammatory activity may be reflected in blood markers like hs-CRP and ESR.
Which blood markers to monitor
Given BPC-157's multi-system effects, a responsible monitoring panel should cover hepatic function, renal function, inflammatory markers, hematology, and growth factor-related markers. Here is the complete list:
Liver enzymes: ALT, AST, and GGT
Even though animal data suggests BPC-157 is hepatoprotective rather than hepatotoxic[7], monitoring liver enzymes is non-negotiable for any systemically administered compound without established human safety data. ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are the primary markers of hepatocellular injury. GGT (gamma-glutamyl transferase) adds sensitivity for biliary and alcohol-related liver stress.
What to look for: Your ALT and AST should remain within their baseline range. Mild fluctuations (5-10 U/L) are normal biological variation. A rise of more than 2x your baseline, or any value exceeding 3x the upper limit of normal (typically >120 U/L), warrants discontinuation and medical evaluation.
Kidney function: creatinine, BUN, eGFR
BPC-157 has shown renoprotective effects in animal models of kidney injury[9], but again, human data is absent. Creatinine and blood urea nitrogen (BUN) are standard markers of kidney filtration capacity. eGFR (estimated glomerular filtration rate) is calculated from creatinine and provides a more clinically meaningful measure of overall kidney function.
What to look for: Creatinine should remain stable. An increase of more than 0.3 mg/dL from your baseline is a signal to investigate. eGFR should remain above 90 mL/min (or stable relative to your baseline if it was already lower).
Inflammatory markers: hs-CRP and ESR
Given BPC-157's anti-inflammatory mechanisms, tracking systemic inflammation provides useful signal. hs-CRP (high-sensitivity C-reactive protein) is the most sensitive blood marker for chronic low-grade inflammation. ESR (erythrocyte sedimentation rate) is complementary and less specific but captures a broader range of inflammatory states.
What to expect: If BPC-157's anti-inflammatory effects translate to humans as they do in rodents, you might see a modest decrease in hs-CRP over 4-8 weeks. Conversely, an unexpected rise in hs-CRP while using BPC-157 could indicate an adverse response or a confounding infection/injury.
Complete blood count (CBC)
A complete blood count captures red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. BPC-157 has shown effects on platelet function and aggregation in animal models[10], making CBC monitoring relevant. Any unexplained drop in platelets, change in white blood cell differential, or shift in hemoglobin deserves attention.
Growth factors: IGF-1 and (if available) VEGF
BPC-157 upregulates growth hormone receptor expression and VEGF in animal models[4]. IGF-1 (insulin-like growth factor 1) is the most accessible blood marker that reflects growth factor activity. While a direct BPC-157-to-IGF-1 link in humans is unproven, tracking IGF-1 provides context on whether growth factor pathways are being stimulated.
What to look for: IGF-1 should remain within its age-appropriate range (typically 100-300 ng/mL for adults, varying by age and sex). A significant rise above your baseline without other explanation (e.g., you didn't start growth hormone therapy simultaneously) may reflect BPC-157's growth factor effects.
Fasting glucose and fasting insulin
While BPC-157 is not primarily known for metabolic effects, some animal studies have shown interactions with the dopaminergic system and indirect effects on glucose metabolism[11]. Tracking fasting glucose and fasting insulin provides a metabolic safety check and allows calculation of HOMA-IR (insulin resistance index), which is a useful general health marker regardless of peptide use.
What changes to expect
Based on the animal literature — and acknowledging the large caveat that animal-to-human translation is uncertain — here is what the research would predict for blood markers in someone using BPC-157:
| Marker | Expected direction | Confidence |
|---|---|---|
| ALT / AST | Stable or slightly decreased | Moderate (animal data) |
| GGT | Stable | Low (limited data) |
| Creatinine / eGFR | Stable | Moderate (animal data) |
| hs-CRP | Slightly decreased | Moderate (animal data) |
| IGF-1 | Possibly slightly increased | Low (indirect evidence) |
| Platelet count | Stable | Low (limited data) |
| Fasting glucose | Stable | Low (limited data) |
The key word is stable. For most markers, the expected outcome is no significant change — BPC-157's proposed mechanisms are tissue-protective, not disruptive. Improvements in inflammatory markers (hs-CRP trending down) or liver enzymes (ALT/AST trending down if previously mildly elevated) would be consistent with the animal literature but are not guaranteed.
Red flags: when to stop and see a doctor
Because BPC-157 lacks human clinical trial data, you need clear stopping criteria. Discontinue use and consult a physician if any of the following occur:
- ALT or AST exceeds 3x the upper limit of normal (typically >120 U/L) or rises more than 2x from your personal baseline
- Creatinine increases by more than 0.3 mg/dL from baseline, or eGFR drops below 60 mL/min
- hs-CRP rises significantly (e.g., from 0.8 to 4.0 mg/L) without an obvious cause like acute infection
- Platelet count drops below 150,000/uL or changes by more than 30% from baseline
- New or worsening symptoms including jaundice, dark urine, unusual bruising, persistent fatigue, or edema
- Any marker moves sharply in a direction opposite to what the animal literature predicts
When to test: a practical schedule
If you are using BPC-157, the following testing schedule represents a responsible minimum:
- Baseline (before starting): Full panel — CMP (liver enzymes, kidney markers, glucose), CBC, hs-CRP, fasting insulin, IGF-1. This is your personal reference point. Without it, you cannot interpret later results.
- 4 weeks into use: Repeat the full panel. This is the first checkpoint to confirm your body is handling the peptide without adverse signals.
- End of cycle + 4 weeks post: Repeat again at the end of your intended use period, and once more 4 weeks after stopping to confirm markers return to baseline.
- Ongoing use: If you use BPC-157 continuously or in repeated cycles, quarterly blood work is a sensible minimum.
The most common mistake people make is skipping the baseline test. A single blood panel has limited interpretive value without a prior reading to compare against. Your ALT of 38 U/L means something very different if your baseline was 22 versus 35.
A note on sourcing and purity
One variable that blood monitoring can help detect but not fully control is peptide purity. BPC-157 is not approved by the FDA for human use and is typically sourced from research chemical suppliers or compounding pharmacies. Contaminants, degradation products, or mislabeled peptides could produce adverse blood marker changes that have nothing to do with BPC-157 itself[12].
If your blood work shows unexpected changes — particularly liver enzyme elevations — the peptide source should be among the first variables you investigate. Third-party testing certificates (certificates of analysis) from the supplier, showing HPLC purity and mass spectrometry confirmation, provide some assurance but are not foolproof.
The bottom line
BPC-157 has a compelling animal research base and an unusually clean safety profile in pre-clinical studies. But pre-clinical is not clinical. The absence of human trial data means that anyone using this peptide is operating in a data gap, and blood monitoring is the single most practical tool for bridging that gap.
A comprehensive baseline, a 4-week follow-up, and clear stopping criteria give you the best chance of catching a problem early — and the confidence to continue if your markers confirm that your body is handling the peptide well.